MeiraGTx signs new New York lab lease and ends sublease early

MeiraGTx Holdings plc said its wholly owned subsidiary, MeiraGTx, LLC, signed a lease on March 31, 2025 for 14,235 square feet of laboratory and related office space at 450 East 29th Street in New York. The landlord is ARE-East River Science Park, LLC. In an 8-K dated April 4, 2025, the company also reported that the subsidiary had moved to end early its existing sublease at the same address. The parent is a Cayman Islands company whose ordinary shares trade on the Nasdaq Global Select Market as MGTX, and its principal executive offices are at 450 East 29th Street, 14th Floor.

The new lease

The lease is expected to start on or before August 1, 2025, but not before July 1, 2025, and the start depends on the landlord finishing its work. Base rent will be $111.00 per square foot per year, plus certain operating expenses and taxes, and it rises by 3% a year. The landlord will contribute $50.00 per square foot toward construction and tenant improvements. The tenant owes no base rent for four months after the start date, and again for three months beginning on the first anniversary. The initial term runs seven years and seven months from the first full calendar month, with an option to extend for five years.

The 8-K says the full text of the lease will be filed with the company's quarterly report for the period ended March 31, 2025.

The sublease that ends early

The subsidiary currently occupies the space under a sublease with ImClone Systems, LLC dated May 31, 2019. That sublease was scheduled to terminate on October 31, 2026. On April 2, 2025, the tenant elected to accelerate the termination, which is now expected on or around August 31, 2025. The 8-K ties the early exit to the new lease, but it does not say whether the two spaces will overlap, or what happens if the landlord's work runs past the planned start date.

The business behind the lab space

The annual report for 2024, filed March 13, 2025, describes MeiraGTx as a vertically integrated, clinical-stage genetic medicines company. It names late-stage programs in Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The overview names those programs and gives no trial results for them.

The company also runs its own manufacturing. It operates a 29,000 square foot viral vector facility in London, which was completed in early 2018, and a 150,000 square foot campus in Shannon, Ireland, which houses a second viral vector facility, a plasmid DNA plant and a quality control hub. The London site holds a manufacturing license from the UK Medicines and Healthcare products Regulatory Agency, granted in May 2018 and re-certified in the second quarter of 2024. The Shannon facility holds two authorizations from the Irish Health Products Regulatory Authority to test products, received in June 2023 and September 2023. The company says its facilities have produced GMP clinical trial material for eight indications.

The report also describes a riboswitch platform that uses oral small molecules to control how much of a therapeutic protein the body makes. Targets named include the metabolic peptides GLP-1, GIP, glucagon, amylin, PYY and leptin, along with cell therapy for oncology and autoimmune diseases and long-term intractable pain. The company calls the platform potentially transformative.

What the filing leaves open

The 8-K does not give the total cost of the lease over its term, and it says nothing about the company's cash position. The company's commitments are now a seven-year lease with scheduled rent increases, a build-out that depends on the landlord's schedule, and an option period that the company can use or let lapse. The timing is set by three dates in the filing: the lease start on or before August 1, 2025, the sublease exit on or around August 31, 2025, and the filing of the full lease with the quarterly report for the period ended March 31, 2025.

Report an error

Companies in this story

MGTXMeiraGTx Holdings plcNASDAQ · United StatesOpen the starter desk